论文部分内容阅读
目的:观察罗格列酮应用于单用胰岛素治疗血糖控制欠佳的2型糖尿病患者的疗效及安全性。方法:102例2型糖尿病患者,空腹血糖控制在7.8-13.9mmol/L范围内,随机分成两组:单用胰岛素治疗组(DM+INS组)50例。联合治疗组(DM+INS+RSG组)52例,在继续应用胰岛素治疗的基础上加服罗格列酮(Rosiglitazone RSG)4mg/d,共三个月。观测两组治疗前后空腹血糖(FPG)及餐后血糖(PPG)、糖化血红蛋白(HbA1C)、甘油三酯(TG)、胆固醇(TC)、高密度脂蛋白(HDL-C)、低密度脂蛋自(LDL-C)、体重指数(BMI)和胰岛素用量的改变。结果:DM+INS+RSG组与DM+INS组洽疗前FPG、PPG、HbA_1C、TC、TG、HDL-C、LDL-C和胰岛素用量无明显统计学差异。(P>0.05)。DM+INS+RSG组治疗后1个月和3个月FPG、PPG、HbA_1C均有明显的下降(P<0.05,P<0.01);胰岛素用量较治疗前减少,而DM+INS组治疗前后FPG、PIG、HbA_1C无明显的改变。Did+INS+RSG组TC、TG、HDL-C、LDL-C等各项指标较治疗前略有增加(P>0.05)。DM+INS+RSG组8例在治疗过程中出现双下肢轻度水肿,5例出现低血糖反应。结论:对单用胰岛素治疗血糖控制欠佳的2型糖尿病患者可加用胰岛素增敏剂罗格列酮治疗,可使血糖和糖化血红蛋白得以良好的控制,减少糖尿病患者每日胰岛素用量,临床毒副作用较小。
OBJECTIVE: To observe the efficacy and safety of rosiglitazone in type 2 diabetes patients with poorly controlled glycemic control by insulin alone. Methods: A total of 102 patients with type 2 diabetes mellitus received fasting blood glucose control in the range of 7.8-13.9mmol / L. They were randomly divided into two groups: 50 in the insulin-treated group (DM + INS group). In the combined treatment group (DM + INS + RSG group), 52 patients received rosiglitazone (RGG) 4mg / d for 3 months after continuing insulin treatment. The levels of fasting blood glucose (FPG) and postprandial blood glucose (PPG), HbA1C, TG, TC, HDL-C and LDL From (LDL-C), body mass index (BMI) and insulin dosage changes. Results: The levels of FPG, PPG, HbA 1 C, TC, TG, HDL-C, LDL-C and insulin before DM treatment in DM + INS + RSG group and DM + INS group were not significantly different. (P> 0.05). The levels of FPG, PPG and HbA 1 C in DM + INS + RSG group decreased significantly at 1 and 3 months after treatment (P <0.05, P <0.01) , PIG, HbA_1C no significant change. The levels of TC, TG, HDL-C and LDL-C in Did + INS + RSG group increased slightly compared with before treatment (P> 0.05). In the DM + INS + RSG group, eight patients had mild edema of both lower extremities and five patients had hypoglycemia. Conclusion: Type 2 diabetes patients with poorly controlled glycemic control can be treated with insulin sensitizer rosiglitazone, which can control blood sugar and glycosylated hemoglobin, reduce the daily insulin dosage, Side effects are small.